Fresh Tracks Therapeutics, Inc.: Nasdaq/NYSE listing notice — Fresh Tracks Therapeutics to be suspended from Nasdaq on Dec 19; plans liquidation and dissolution

Fresh Tracks Therapeutics, Inc.

Stock to be suspended from Nasdaq at open on Dec 19, 2023; expects trading to begin on OTC market.
Board withdrew appeal of Nasdaq delisting notice on Dec 15 in preparation for planned dissolution.
Special meeting of stockholders reconvened for Dec 27 to vote on Plan of Liquidation and Dissolution.
If stockholders do not approve dissolution, company intends to seek judicial dissolution, which would reduce cash distributions.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

Fresh Tracks Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding other.

Exchange: nasdaq
Notice: noncompliance notice

Exact text from the filing

October 17, 2023, the Company requested an appeal (the “Appeal”) through a hearing before the Nasdaq Hearings Panel (the “Panel”), which stayed the suspension and delisting action pending the Panel’s decision. On December 15, 2023, in preparation for the planned liquidation and dissolution (the “Dissolution”) of the Company, the Company’s Board of Directors approved the withdrawal of the Appeal and authorized the officers of the Company to seek to delist the Company’s common stock from Nasdaq. The Company also notified Nasdaq of its decision to withdraw the Appeal. Also on December 15, 2023, f

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001628280-23-041723

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.